Macrogenics Inc (MGNX)
4.06
-0.23
(-5.36%)
USD |
NASDAQ |
Jun 26, 15:37
Macrogenics Research and Development Expense (Annual): 166.58M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 166.58M |
| December 31, 2022 | 207.03M |
| December 31, 2021 | 214.58M |
| December 31, 2020 | 193.20M |
| December 31, 2019 | 195.31M |
| December 31, 2018 | 190.83M |
| December 31, 2017 | 147.23M |
| Date | Value |
|---|---|
| December 31, 2016 | 122.09M |
| December 31, 2015 | 98.27M |
| December 31, 2014 | 70.19M |
| December 31, 2013 | 46.58M |
| December 31, 2012 | 45.43M |
| December 31, 2011 | 41.09M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
166.58M
Minimum
2023
214.58M
Maximum
2021
195.34M
Average
195.31M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Moderna Inc | 4.845B |
| Allurion Technologies Inc | 27.69M |
| Novavax Inc | 737.50M |
| Viking Therapeutics Inc | 63.81M |
| Verrica Pharmaceuticals Inc | 20.30M |